claritypharmaceuticals.comCrawled Oct 27, 2026
Clarity’s pipeline is underpinned by SAR Technology that enables highly targeted radiopharmaceuticals for the diagnosis and treatment of serious diseases
Theranostic radiopharmaceutical with increased specificity and in-vivo stability, being developed for diagnosing and treating cancers that express GRPr
Clarity Pharmaceuticals launched “Insight”, a quarterly newsletter focussed on the latest news in the imaging industry.
A preliminary assessment of the 8 GBq 67Cu-SAR-bisPSMA dose in the SECuRE trial (NCT04868604) evaluates safety and efficacy across 19 participants.
Clarity Pharmaceuticals publishes *Insight*, a quarterly newsletter covering imaging industry updates, such as Genentech’s anti-C-MET trial and the ZEPHIR trial.
Clarity Pharmaceuticals advances its lead product, SARTATE, into clinical trials for cancers including neuroendocrine tumors and childhood cancers, based on research by Prof Suzanne Smith.
Clarity Pharmaceuticals is awarded a $2,513,000 CRC-P grant from the Australian Government to expand its capabilities in radiopharmaceutical development.
Clarity Pharmaceuticals receives a EUR950,000 grant from the Belgium government’s Wallonia COOTECH program to support its research.
Personalised medicine and innovative radiopharmaceutical technology to support targeted therapy drug development
Clarity's scientific advisory board is comprised of global thought leaders with extensive capabilities, expertise and experience in developing radiopharmaceutical products
Clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and diagnostic) products for children and adults with cancer
Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.